Skip to main content

Articles

Treatment of Advanced Breast Cancer: A Clinical Pharmacy Perspective

Depending on the patient’s needs, the clinical pharmacist may also work with other staff members, such as financial counselors or social workers, to optimize patient care. Similarly, clinical pharmacists confer with specialty pharmacists to ensure that insurance issues are resolved so that the patient receives timely access to treatment.

Read More ›

The Importance of Patient Education: A Nurse’s Perspective

It is exciting to see that patients with advanced breast cancer are able to receive additional treatment options, because a primary concern of patients with stage IV breast cancer is a lack of awareness of laboratory and clinical research targeted for those battling advanced disease.

Read More ›

Increasing Focus on Value Related to Cancer Drugs: A Payer Perspective

Outside of initial clinical trials, few tools are available to assess the real-world impact of breast cancer on patients. In a research letter published in February 2017 in the Journal of the American Medical Association, the authors compared the impact of several new cancer drugs on progression-free survival (PFS) with their impact on the patient’s quality of life and annual cost.3

Read More ›

A Look at SIRT Y-90 and the SARAH Trial
Dr. Valérie Vilgrain discusses SIRT Y-90 and the results of the SARAH trial.
Read More ›

Project Aims to Prevent Future Infusion-Related Reactions
An infusion-related reaction documentation tool and grading system and its integration into the electronic health record (EHR) is expected to better identify patients at risk for future reactions, and improve communication among oncology team members.
Read More ›

Managing Immune-Related Toxicities in Patients with Lung Cancer
Immune-related toxicities in patients with NSCLC can be traced back to the mechanism of action of immune checkpoint inhibitors.
Read More ›

A Conversation with Patrick J. Medina, PharmD, BCOP
Patrick J. Medina, PharmD, BCOP, is Professor of Clinical and Administrative Sciences at the University of Oklahoma College of Pharmacy in Tulsa.
Read More ›

Real-world experience at the University of Texas M.D. Anderson Cancer Center, Houston, showed that the most frequent immune-related adverse events leading to emergency department visits for patients treated with immune checkpoint inhibitors were diarrhea, colitis, pneumonitis, and dermatitis.
Read More ›

The current practice in the treatment of advanced kidney cancer and some other cancers is to continue treatment with immune checkpoint inhibitors until disease progression, and sometimes even longer.
Read More ›

Compliance with orders for granulocyte colony-stimulating factors (G-CSFs) is suboptimal, and inadequate prophylaxis was directly tied to hospital admissions, according to results of a recent clinical trial from the University of Pennsylvania Health System.
Read More ›

Page 113 of 289